X

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omega-3-acid ethyl esters (Primary)
Indications Atrial fibrillation
Focus Therapeutic Use
Sponsors GSK; Reliant Pharmaceuticals

Most Recent Events

15 Nov 2010 Results published online in the Journal of the American Medical Association.
15 Nov 2010 Study findings were presented at the American Heart Association's Scientific Sessions and published online in the Journal of the American Medical Association, according to a GlaxoSmithKline media release.
30 Aug 2010 Actual end date changed from Feb 2010 to Jan 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com